Exendin 9-39
Morbid Obesity
Hvidovre University HospitalUNKNOWNN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
61 Active assets in the Morbid Obesity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lidocaine Instituto Mexicano del Seguro Social | Phase 4 | BBB |
Propofol G.Gennimatas General Hospital | Phase 4 | BBB |
Chenodeoxycholic Acid Hvidovre University Hospital | Phase 4 | BBB |
Colesevelam Hvidovre University Hospital | Phase 4 | BBB |
Ramifentanyl Hospital dos Lusíadas | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Exendin 9-39 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →